Literature DB >> 9146891

Alteration of flow-induced dilatation in mesenteric resistance arteries of L-NAME treated rats and its partial association with induction of cyclo-oxygenase-2.

D Henrion1, E Dechaux, F J Dowell, J Maclour, J L Samuel, B I Lévy, J B Michel.   

Abstract

1. We investigated the response to pressure (myogenic tone) and flow of rat mesenteric resistance arteries cannulated in an arteriograph which allowed the measurement of intraluminal diameter for controlled pressures and flows. Rats were treated for 3 weeks with NG-nitro-L-arginine methyl ester (L-NAME, 50 mg kg-1 day-1) or L-NAME plus the angiotensin I converting enzyme inhibitor (ACEI) quinapril (10 mg kg-1 day-1). 2. Mean blood pressure increased significantly in chronic L-NAME-treated rats (155 +/- 4 mmHg, n = 8, vs control 121 +/- 6 mmHg, n = 10; P < 0.05). L-NAME-treated rats excreted significantly more dinor-6-keto prostaglandin F1 alpha (dinor-6-keto PGF1 alpha), the stable urinary metabolite of prostacyclin, than control rats. The ACEI prevented the rise in blood pressure and the rise in urinary dinor-6-keto PGF1 alpha due to L-NAME. 3. Isolated mesenteric resistance arteries, developed myogenic tone in response to stepwise increases in pressure (42 +/- 6 to 847 +/- 10 mN mm-1, from 25 to 150 mmHg, n = 9). Myogenic tone was not significantly affected by the chronic treatment with L-NAME or L-NAME + ACEI. 4. Flow (100 microliters min-1) significantly attenuated myogenic tone by 50 +/- 6% at 150 mmHg (n = 10). Flow-induced dilatation was significantly attenuated by chronic L-NAME to 22 +/- 6% at 150 mmHg (n = 10, p = 0.0001) and was not affected in the L-NAME + ACEI group. 5. Acute in vitro NG-nitro-L-arginine (L-NOARG, 10 microM) significantly decreased flow-induced dilation in control but not in L-NAME or L-NAME + ACEI rats. Both acute indomethacin (10 microM) and acute NS 398 (cyclo-oxygenase-2 (COX-2) inhibitor, 1 microM) did not change significantly flow-induced dilatation in controls but they both decreased flow-induced dilatation in the L-NAME and L-NAME + ACEI groups. Acute Hoe 140 (bradykinin receptor inhibitor, 1 microM) induced a significant contraction of the isolated mesenteric arteries which was the same in the 3 groups. 6. Immunofluorescence analysis of COX-2 showed that the enzyme was expressed in resistance mesenteric arteries in L-NAME and L-NAME + ACEI groups but not in control. COX-1 expression was identical in all 3 groups. 7. We conclude that chronic inhibition of nitric oxide synthesis is associated with a decreased flow-induced dilatation in resistance mesenteric arteries which was compensated by an overproduction of vasodilator prostaglandins resulting in part from COX-2 expression. The decrease in flow-induced dilatation was prevented by the ACEI, quinapril.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9146891      PMCID: PMC1564658          DOI: 10.1038/sj.bjp.0701109

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  29 in total

1.  COX-2 contributes to the maintenance of flow-induced dilation in arterioles of eNOS-knockout mice.

Authors:  Dong Sun; Hong Liu; Changdong Yan; Azita Jacobson; Caroline Ojaimi; An Huang; Gabor Kaley
Journal:  Am J Physiol Heart Circ Physiol       Date:  2006-04-21       Impact factor: 4.733

2.  Endoplasmic reticulum stress is involved in cardiac damage and vascular endothelial dysfunction in hypertensive mice.

Authors:  Modar Kassan; Maria Galán; Megan Partyka; Zubaida Saifudeen; Daniel Henrion; Mohamed Trebak; Khalid Matrougui
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-04-26       Impact factor: 8.311

3.  Chronic nitric oxide synthase inhibition blunts endothelium-dependent function of conduit coronary arteries, not arterioles.

Authors:  David G Ingram; Sean C Newcomer; Elmer M Price; Kevin E Eklund; Richard M McAllister; M Harold Laughlin
Journal:  Am J Physiol Heart Circ Physiol       Date:  2007-01-26       Impact factor: 4.733

4.  Vascular bed heterogeneity in age-related endothelial dysfunction with respect to NO and eicosanoids.

Authors:  R L Matz; M A de Sotomayor; C Schott; J C Stoclet; R Andriantsitohaina
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

5.  Are cyclooxygenase-2 and nitric oxide involved in the dyskinesia of Parkinson's disease induced by L-DOPA?

Authors:  Mariza Bortolanza; Fernando E Padovan-Neto; Roberta Cavalcanti-Kiwiatkoski; Maurício Dos Santos-Pereira; Miso Mitkovski; Rita Raisman-Vozari; Elaine Del-Bel
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-07-05       Impact factor: 6.237

6.  DOCA-salt hypertension impairs artery function in rat middle cerebral artery and parenchymal arterioles.

Authors:  Nusrat Matin; Paulo W Pires; Hannah Garver; William F Jackson; Anne M Dorrance
Journal:  Microcirculation       Date:  2016-10       Impact factor: 2.628

7.  Notch3 is a major regulator of vascular tone in cerebral and tail resistance arteries.

Authors:  E J Belin de Chantemèle; K Retailleau; F Pinaud; E Vessières; A Bocquet; A L Guihot; B Lemaire; V Domenga; C Baufreton; L Loufrani; A Joutel; D Henrion
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-09-25       Impact factor: 8.311

8.  Effects of chronic nitric oxide synthase inhibition on endothelium-dependent and -independent relaxation in arteries that perfuse skeletal muscle of swine.

Authors:  S C Newcomer; J C Taylor; R M McAllister; M H Laughlin
Journal:  Endothelium       Date:  2008 Jan-Feb

9.  Altered arachidonic acid metabolism via COX-1 and COX-2 contributes to the endothelial dysfunction of penile arteries from obese Zucker rats.

Authors:  A Sánchez; C Contreras; N Villalba; P Martínez; A C Martínez; A Bríones; M Salaíces; A García-Sacristán; M Hernández; D Prieto
Journal:  Br J Pharmacol       Date:  2010-01-15       Impact factor: 8.739

10.  Cyclooxygenase-2 is upregulated in copper-deficient rats.

Authors:  Dale A Schuschke; Ayotunde S O Adeagbo; Phani K Patibandla; Uchechi Egbuhuzo; Rafael Fernandez-Botran; W Thomas Johnson
Journal:  Inflammation       Date:  2009-10       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.